Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 5/20 | 0.36 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604476 | 1.00 | MAPKAPK2 (0.39) | MAPKAPK2CCNT1CDK9KITGPR119 | |
| SCHEMBL3623096 | 0.97 | MAPKAPK2 (0.41) | MAPKAPK2CCNT1CDK9KITGPR119 | |
| SCHEMBL3623094 | 0.97 | MAPKAPK2 (0.41) | MAPKAPK2CCNT1CDK9KITGPR119 | |
| SCHEMBL13442241 | 0.89 | MAPKAPK2 (0.41) | MAPKAPK2CCNT1CDK9KITGPR119 | |
| SCHEMBL3610339 | 0.89 | KIT (0.46) | MAPKAPK2KITGPR119CKS1BSKP1 | |
| SCHEMBL3610342 | 0.89 | KIT (0.46) | MAPKAPK2KITGPR119CKS1BSKP1 | |
| SCHEMBL14283117 | 0.89 | KIT (0.41) | MAPKAPK2CCNT1CDK9KITCKS1B | |
| SCHEMBL3616501 | 0.85 | GPR119 (0.40) | MAPKAPK2KITGPR119TBK1NR1H2 | |
| SCHEMBL3616500 | 0.85 | GPR119 (0.40) | MAPKAPK2KITGPR119TBK1NR1H2 | |
| SCHEMBL3605830 | 0.84 | MAPKAPK2 (0.48) | MAPKAPK2CDK9KITTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| EP-2069333-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | Novartis Ag (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008034600-A1 | PYRROLE DERIVATIVES USEFUL FOR THE TREATMENT OF CYTOKINE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105664-A1 | ORGANIC COMPOUNDS | SLCO1B3, SLCO1B1, SLC10A6 | MAPKAPK2 4395/4885CCNT1 202/4885CDK9 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.